{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:41:42Z","timestamp":1769150502878,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"publisher","award":["cstc2019jcyj-msxmX0859"],"award-info":[{"award-number":["cstc2019jcyj-msxmX0859"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601837"],"award-info":[{"award-number":["81601837"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003075","name":"Chongqing Municipal Public Health Bureau, Chongqing People's Municipal Government","doi-asserted-by":"publisher","award":["2019QNXM028"],"award-info":[{"award-number":["2019QNXM028"]}],"id":[{"id":"10.13039\/501100003075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Autoimmune hepatitis (AIH) is a liver disease characterized by the autoimmune-induced injury of hepatocytes which can lead to cirrhosis and hepatic failure. The diagnosis and disease management of AIH patients remain challenging due to the diversity of clinical phenotypes and the presence of confounders such as alcohol and viruses. Recently, EN-RAGE and sRAGEs have been implicated in inflammatory-immune response. Nonetheless, their natural behaviour and relationship to disease activity as well as clinical predictive values in AIH development or therapy-induced remission have not been reported.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Sixty-seven AIH patients and thirty gender- and age-matched healthy controls (HC) were enrolled. The serum concentrations of EN-RAGE, sRAGE and their ratio (EN-RAGE\/sRAGE) in these subjects were measured by ELISA. Besides, the correlations of three parameters with clinical features and therapeutic response were analyzed, respectively. Furthermore, their potential predictive values for monitoring the AIH progression and therapeutic response were also evaluated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Higher serum EN-RAGE, lower sRAGE and higher EN-RAGE\/sRAGE value were observed in AIH patients. EN-RAGE and sRAGE as well as EN-RAGE\/sRAGE were correlated with liver necroinflammation parameters, cirrhosis occurrence and therapeutic response. In addition, we identified that EN-RAGE\/sRAGE, EN-RAGE and sRAGE had valuable predicting power for AIH patients, AIH patients with normal ALT and cirrhosis incidence, respectively. More importantly, EN-RAGE\/sRAGE also exerted predicting power for the remission in AIH patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>AIH patients rendered distinct patterns of serum EN-RAGE, sRAGE or EN-RAGE\/sRAGE compared to healthy controls. Moreover, these three parameters exhibited potentials as novel biomarkers for AIH diagnosis and prognosis evaluation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12967-020-02556-w","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T12:02:59Z","timestamp":1602244979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Assessment of EN-RAGE, sRAGE and EN-RAGE\/sRAGE as potential biomarkers in patients with autoimmune hepatitis"],"prefix":"10.1186","volume":"18","author":[{"given":"Rui","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3882-7527","authenticated-orcid":false,"given":"Liang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"2556_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cld.873","volume":"15","author":"DN Assis","year":"2020","unstructured":"Assis DN. Immunopathogenesis of autoimmune hepatitis. Clin Liver Dis (Hoboken). 2020;15:129\u201332.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"4","key":"2556_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5009\/gnl19261","volume":"14","author":"A Tanaka","year":"2020","unstructured":"Tanaka A. Autoimmune Hepatitis: 2019 Update. Gut Liver. 2020;14(4):430\u20138.","journal-title":"Gut Liver"},{"issue":"Suppl 2","key":"2556_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000440747","volume":"33","author":"DG Tiniakos","year":"2015","unstructured":"Tiniakos DG, Brain JG, Bury YA. Role of histopathology in autoimmune hepatitis. Dig Dis. 2015;33(Suppl 2):53\u201364.","journal-title":"Dig Dis"},{"key":"2556_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/17474124.2018.1453356","volume":"12","author":"AJ Czaja","year":"2018","unstructured":"Czaja AJ. Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. Expert Rev Gastroenterol Hepatol. 2018;12:547\u201364.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2556_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","volume":"69","author":"BI Hudson","year":"2018","unstructured":"Hudson BI, Lippman ME. Targeting RAGE signaling in inflammatory disease. Annu Rev Med. 2018;69:349\u201364.","journal-title":"Annu Rev Med"},{"key":"2556_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/907078","volume":"2012","author":"B Meijer","year":"2012","unstructured":"Meijer B, Gearry RB, Day AS. The Role of S100A12 as a SystemicMarker of Inflammation. Int J Inflamm. 2012;2012:1\u20136.","journal-title":"Int J Inflamm"},{"key":"2556_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1189\/jlb.0306170","volume":"81","author":"D Foell","year":"2007","unstructured":"Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007;81:28\u201337.","journal-title":"J Leukoc Biol"},{"key":"2556_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/1751-2980.12012","volume":"14","author":"F van de Logt","year":"2013","unstructured":"van de Logt F, Day AS. S100A12: a noninvasive marker of inflammation in inflammatory bowel disease. J Dig Dis. 2013;14:62\u20137.","journal-title":"J Dig Dis"},{"key":"2556_CR9","doi-asserted-by":"publisher","first-page":"2868373","DOI":"10.1155\/2020\/2868373","volume":"2020","author":"A Carvalho","year":"2020","unstructured":"Carvalho A, Lu J, Francis JD, Moore RE, Haley KP, Doster RS, Townsend SD, Johnson JG, Damo SM, Gaddy JA. S100A12 in digestive diseases and health: a scoping review. Gastroenterol Res Pract. 2020;2020:2868373.","journal-title":"Gastroenterol Res Pract"},{"key":"2556_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2017.07.001","volume":"49","author":"S Ahmad","year":"2018","unstructured":"Ahmad S, Khan H, Siddiqui Z, Khan MY, Rehman S, Shahab U, Godovikova T, Silnikov V. Moinuddin: AGEs, RAGEs and s-RAGE; friend or foe for cancer. Semin Cancer Biol. 2018;49:44\u201355.","journal-title":"Semin Cancer Biol"},{"key":"2556_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-3083.2012.02691.x","volume":"75","author":"CY Ma","year":"2012","unstructured":"Ma CY, Ma JL, Jiao YL, Li JF, Wang LC, Yang QR, You L, Cui B, Chen ZJ, Zhao YR. The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus. Scand J Immunol. 2012;75:614\u201322.","journal-title":"Scand J Immunol"},{"key":"2556_CR12","first-page":"89","volume":"90","author":"T Aversa","year":"2018","unstructured":"Aversa T, Ruggeri RM, Corica D, Cristani MT, Mirabelli S, Vicchio TM, Trimarchi F, De Luca F, Wasniewska M. Serum levels of the soluble receptor for advanced glycation end products are reduced in children with hashimoto's thyroiditis. Horm Res Paediatr. 2018;90:89\u201390.","journal-title":"Horm Res Paediatr"},{"key":"2556_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep21890","author":"DQ Zhang","year":"2016","unstructured":"Zhang DQ, Wang R, Li T, Zhou JP, Chang GQ, Zhao N, Yang LN, Zhai H, Yang L. Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barre syndrome. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep21890.","journal-title":"Sci Rep"},{"key":"2556_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/liv.14062","volume":"39","author":"I Doycheva","year":"2019","unstructured":"Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: current and future therapeutic options. Liver Int. 2019;39:1002\u2013133.","journal-title":"Liver Int"},{"key":"2556_CR15","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.4049\/jimmunol.181.6.4272","volume":"181","author":"Y Chen","year":"2008","unstructured":"Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008;181:4272\u20138.","journal-title":"J Immunol"},{"key":"2556_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14309\/ctg.0000000000000040","volume":"10","author":"D Ivancovsky-Wajcman","year":"2019","unstructured":"Ivancovsky-Wajcman D, Zelber-Sagi S, Fliss Isakov N, Webb M, Zemel M, Shibolet O, Kariv R. Serum soluble receptor for age (sRAGE) levels are associated with unhealthy lifestyle and nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2019;10:1\u201310.","journal-title":"Clin Transl Gastroenterol"},{"key":"2556_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.metabol.2018.01.023","volume":"83","author":"SA Palma-Duran","year":"2018","unstructured":"Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, Papatheodoridis G, Combet E. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;83:120\u20137.","journal-title":"Metabolism"},{"key":"2556_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169\u201376.","journal-title":"Hepatology"},{"key":"2556_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929\u201338.","journal-title":"J Hepatol"},{"key":"2556_CR20","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1021\/acs.jmedchem.7b00058","volume":"60","author":"S Bongarzone","year":"2017","unstructured":"Bongarzone S, Savickas V, Luzi F, Gee AD. Targeting the receptor for advanced glycation endproducts (RAGE): a medicinal chemistry perspective. J Med Chem. 2017;60:7213\u201332.","journal-title":"J Med Chem"},{"key":"2556_CR21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2741\/s215","volume":"3","author":"MA van Zoelen","year":"2011","unstructured":"van Zoelen MA, Achouiti A, van der Poll T. RAGE during infectious diseases. Front Biosci (Schol Ed). 2011;3:1119\u201332.","journal-title":"Front Biosci (Schol Ed)"},{"key":"2556_CR22","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.2741\/e178","volume":"2","author":"S Yamagishi","year":"2010","unstructured":"Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed). 2010;2:1184\u201395.","journal-title":"Front Biosci (Elite Ed)"},{"key":"2556_CR23","doi-asserted-by":"publisher","first-page":"8465083","DOI":"10.1155\/2020\/8465083","volume":"2020","author":"P Borsky","year":"2020","unstructured":"Borsky P, Fiala Z, Andrys C, Beranek M, Hamakova K, Malkova A, Svadlakova T, Krejsek J, Palicka V, Borska L, Rehacek V. Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris. Mediators Inflamm. 2020;2020:8465083.","journal-title":"Mediators Inflamm"},{"key":"2556_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1021\/acschemneuro.9b00678","volume":"11","author":"E Angelopoulou","year":"2020","unstructured":"Angelopoulou E, Paudel YN, Piperi C. Unraveling the role of receptor for advanced glycation end products (RAGE) and its ligands in myasthenia gravis. ACS Chem Neurosci. 2020;11:663\u201373.","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"2556_CR25","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s40618-020-01231-7","volume":"43","author":"RM Ruggeri","year":"2020","unstructured":"Ruggeri RM, Barbalace MC, Cristani MT, Alibrandi A, Giovinazzo S, Giuffrida G, Trimarchi F, Cannavo S, Campenni A. Serum levels of advanced glycation end products (AGEs) are increased and their soluble receptor (sRAGE) reduced in Hashimoto's thyroiditis. J Endocrinol Invest. 2020;43(9):1337\u2013422.","journal-title":"J Endocrinol Invest"},{"key":"2556_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1172\/JCI200114002","volume":"108","author":"AM Schmidt","year":"2001","unstructured":"Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949\u201355.","journal-title":"J Clin Invest"},{"key":"2556_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/hep.20732","volume":"42","author":"JJ Feld","year":"2005","unstructured":"Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53\u201362.","journal-title":"Hepatology"},{"key":"2556_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev-immunol-032712-095937","volume":"31","author":"G Wick","year":"2013","unstructured":"Wick G, Grundtman C, Mayerl C, Wimpissinger TF, Feichtinger J, Zelger B, Sgonc R, Wolfram D. The immunology of fibrosis. Annu Rev Immunol. 2013;31:107\u201335.","journal-title":"Annu Rev Immunol"},{"key":"2556_CR29","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1007\/s10620-016-4254-7","volume":"61","author":"AJ Montano-Loza","year":"2016","unstructured":"Montano-Loza AJ, Thandassery RB, Czaja AJ. Targeting hepatic fibrosis in autoimmune hepatitis. Dig Dis Sci. 2016;61:3118\u2013399.","journal-title":"Dig Dis Sci"},{"key":"2556_CR30","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1038\/srep08931","volume":"5","author":"S Mulrennan","year":"2015","unstructured":"Mulrennan S, Baltic S, Aggarwal S, Wood J, Miranda A, Frost F, Kaye J, Thompson PJ. The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. Sci Rep. 2015;5:8931.","journal-title":"Sci Rep"},{"key":"2556_CR31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jid.2016.10.040","volume":"137","author":"J Zhao","year":"2017","unstructured":"Zhao J, Zhong A, Friedrich EE, Jia S, Xie P, Galiano RD, Mustoe TA, Hong SJ. S100A12 induced in the epidermis by reduced hydration activates dermal fibroblasts and causes dermal fibrosis. J Invest Dermatol. 2017;137:650\u20139.","journal-title":"J Invest Dermatol"},{"key":"2556_CR32","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1177\/2050640619872408","volume":"7","author":"S Pape","year":"2019","unstructured":"Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United Eur Gastroenterol J. 2019;7:1156\u201363.","journal-title":"United Eur Gastroenterol J"},{"key":"2556_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3899\/jrheum.170438","volume":"45","author":"F Gohar","year":"2018","unstructured":"Gohar F, Anink J, Moncrieffe H, Van Suijlekom-Smit LWA, Prince FHM, van Rossum MAJ, Dolman KM, Hoppenreijs E, Ten Cate R, Ursu S, et al. S100A12 is associated with response to therapy in juvenile idiopathic arthritis. J Rheumatol. 2018;45:547\u201354.","journal-title":"J Rheumatol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02556-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02556-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02556-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T16:48:29Z","timestamp":1633884509000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02556-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2556"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02556-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients were consented for serum acquisition per institutional review board (IRB)-approved protocol.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no competing interests regarding the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}